Fighting the stigmatization of monkeypox patients
When disease outbreaks occur, health experts are not only faced with the challenge of getting good information out to people – they also must battle […]
When disease outbreaks occur, health experts are not only faced with the challenge of getting good information out to people – they also must battle […]
State and city governments are walking a fine line as they move to confront the monkeypox outbreak, trying to spread awareness of the disease — which […]
In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning […]
Not very long ago, contracting HIV was an effective death sentence; today, there are treatments that allow the condition to be managed but not eradicated. […]
A recently-released study by the Coalition for Applied Modeling for Prevention (CAMP) and funded by the Centers for Disease Control and Prevention (CDC) highlights the […]
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after […]
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries. The […]
Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of […]
Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it […]
The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for […]
Researchers discovered a highly virulent variant of HIV in the Netherlands that genetic sequence analysis suggests has been circulating since the 1990s. Approximately 38 million […]
A woman with HIV who received a stem cell transplant to treat acute myeloid leukaemia (AML) appears to have been cured of the infection according […]
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties […]
US pharma giant Gilead Sciences has accused a network of unauthorised suppliers and distributors of selling more than $250 million of counterfeit versions of its […]
GlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis […]
A digital pill that records when it is taken has been shown to be highly effective at helping patients adhere to pre-exposure prophylaxis (PrEP) treatment […]
Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the […]
People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable […]
Shots: The ongoing BICSTaR study evaluates the antiviral effectiveness & safety of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in 1135 patients […]
CVS Caremark recently launched efforts to better prevent, detect and treat sickle cell disease, HIV and cardiovascular disease. CVS Caremark CMO Sree Chaguturu shared how […]
Shots: ViiV Healthcare has reported a regulatory submission to the US FDA for the approval of a new dispersible tablet formulation of the fixed-dose combination […]
Shots: The P-III TANGO study evaluating the antiviral efficacy and safety of dolutegravir/lamivudine switching to a 2DR vs TAF based regimens in HIV-infected adults who […]
Shots: Shionogi to receive $27.2M up front, $20.4M upon the achievement of a clinical milestone along with royalties on net sales of S-365598 (HIV integrase […]
Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021 marks 40 years since the first cases […]
Pfizer’s RSV Vaccine enters in the late-stage of clinical trials As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market […]
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine […]
The global focus on the development and distribution of COVID-19 vaccines over the past year has been a reminder that there are still many other […]
Shots: The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & […]
Shots: The P-II/III CAPELLA trial involves assessing lenacapavir (SC, every 6mos.) vs PBO in 36 participants in a ratio (2:1) with multi-drug resistant HIV-1 infection […]
Shots: The P-IIa POC study involves assessing GSK3640254 (GSK’254, qd) in 34 treatment-naïve adults with HIV. The study is divided into 2 parts- in part […]
Shots: The P- IIIb ATLAS-2M study involves assessing long-acting cabotegravir and rilpivirine regimen for the treatment of HIV The ATLAS-2M 96wks. data reinforce the 1EPs […]
US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out […]
The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed […]
Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion […]
Shots: Gristone to receive $60M at closing, including $30M up front and a $30M as an equity investment at a premium and is eligible to […]
The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships […]
The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection […]
ViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients supported by a mobile app. ViiV, a […]
ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by […]
Shots: The approval is based on P1093 & ODYSSEY (Penta20) studies assessing safety, tolerability & dose-finding of Tivicay (5mg) in pediatric patients aged 4wks.-18yrs. while […]
Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by […]
GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after the FDA granted Breakthrough Therapy Designation for […]
Shots: This BT designation is based on P-IIb/III HPTN 083 study assessing cabotegravir (q8w) vs. FTC/TDF tablets (qd PO, 200/300 mg) in a study population […]
UnitedHealthcare sent a notice to plan members stating that it would no longer cover Descovy to prevent HIV, while Truvada – after it goes generic […]
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The […]
Copyright © 2024 | WordPress Theme by MH Themes